Literature DB >> 28838714

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.

Nobukazu Agatsuma1, Yuto Yasuda2, Hiroaki Ozasa3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28838714     DOI： 10.1016/j.jtho.2017.04.028

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.

Authors:  Roberto Bei; Monica Benvenuto; Chiara Focaccetti; Sara Fazi; Marta Moretti; Daniela Nardozi; Valentina Angiolini; Sara Ciuffa; Loredana Cifaldi; Raffaele Carrano; Camilla Palumbo; Martino Tony Miele; Riccardo Bei; Giovanni Barillari; Vittorio Manzari; Enrico De Smaele; Andrea Modesti; Laura Masuelli
Journal:  J Transl Med       Date:  2022-06-25       Impact factor: 8.440

Review 2.  In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM).

Authors:  Anand S Singh; Richard Heery; Steven G Gray
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

3.  EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.

Authors:  Youri Hoogstrate; Wies Vallentgoed; Johan M Kros; Iris de Heer; Maurice de Wit; Marica Eoli; Juan Manuel Sepulveda; Annemiek M E Walenkamp; Jean-Sebastien Frenel; Enrico Franceschi; Paul M Clement; Micheal Weller; Martin E van Royen; Peter Ansell; Jim Looman; Earle Bain; Marie Morfouace; Thierry Gorlia; Vassilis Golfinopoulos; Martin van den Bent; Pim J French
Journal:  Neurooncol Adv       Date:  2019-12-09

4.  Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas.

Authors:  Ya Gao; Wies R Vallentgoed; Pim J French
Journal:  Cancers (Basel)       Date:  2018-12-04       Impact factor: 6.639

5.  Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.

Authors:  Maurice de Wit; Ya Gao; Darlene Mercieca; Iris de Heer; Bart Valkenburg; Martin E van Royen; Joachim Aerts; Peter Sillevis Smitt; Pim French
Journal:  EBioMedicine       Date:  2020-06-05       Impact factor: 8.143
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.